Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se

Referenser

Alfred, A., Taylor, P. C., Dignan, F., El-Ghariani, K., Griffin, J., Gennery, A. R., . . . Scarisbrick, J. J. (2017). The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol, 177(2), 287-310. doi:10.1111/bjh.14537

Assaf, C., Bagot, M., Dummer, R., Duvic, M., Gniadecki, R., Knobler, R., . . . Whittaker, S. (2006). Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol, 155(2), 261-266. doi:10.1111/j.1365-2133.2006.07329.x

Beynon, T., Radcliffe, E., Child, F., Orlowska, D., Whittaker, S., Lawson, S., . . . Harding, R. (2014). What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence. Br J Dermatol, 170(3), 599-608. doi:10.1111/bjd.12644

Bradford, P. T., Devesa, S. S., Anderson, W. F., & Toro, J. R. (2009). Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood, 113(21), 5064-5073. doi:10.1182/blood-2008-10-184168

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., . . . Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. doi:10.1007/s11606-010-1475-x

Burg, G., & Dummer, R. (2000). Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma, 1 Suppl 1, S41-44. 

Carter, J., & Zug, K. A. (2009). Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol, 60(1), 39-50. doi:10.1016/j.jaad.2008.08.043

Cheeley, J., Sahn, R. E., DeLong, L. K., & Parker, S. R. (2013). Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol, 68(2), 247-254. doi:10.1016/j.jaad.2012.07.013

Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., . . . United Kingdom National Cancer Research, I. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 32(27), 3059-3068. doi:10.1200/JCO.2013.54.8800

Chung, M., Lee, J., Terasawa, T., Lau, J., & Trikalinos, T. A. (2011). Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med, 155(12), 827-838. doi:10.7326/0003-4819-155-12-201112200-00005

Clarke, C. A., Morton, L. M., Lynch, C., Pfeiffer, R. M., Hall, E. C., Gibson, T. M., . . . Engels, E. A. (2013). Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer, 109(1), 280-288. doi:10.1038/bjc.2013.294

Coulter, I. D., Hardy, M. L., Morton, S. C., Hilton, L. G., Tu, W., Valentine, D., & Shekelle, P. G. (2006). Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer. J Gen Intern Med, 21(7), 735-744. doi:10.1111/j.1525-1497.2006.00483.x

Duarte, R. F., Boumendil, A., Onida, F., Gabriel, I., Arranz, R., Arcese, W., . . . Dreger, P. (2014). Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol, 32(29), 3347-3348. doi:10.1200/JCO.2014.57.5597

Dummer, R., Quaglino, P., Becker, J. C., Hasan, B., Karrasch, M., Whittaker, S., . . . Knobler, R. (2012). Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol, 30(33), 4091-4097. doi:10.1200/jco.2011.39.8065

Duvic, M. (2015). Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sezary syndrome. Hematology Am Soc Hematol Educ Program, 2015, 529-544. doi:10.1182/asheducation-2015.1.529

Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., . . . Yocum, R. C. (2001). Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol, 19(9), 2456-2471. doi:10.1200/jco.2001.19.9.2456

Duvic, M., Olsen, E. A., Omura, G. A., Maize, J. C., Vonderheid, E. C., Elmets, C. A., . . . Sanders, D. Y. (2001). A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol, 44(6), 940-947. doi:10.1067/mjd.2001.113478

Elder, D. E., Massi, D., Scolyer, R. A., & Willemeze, R. (2018). WHO Classification of Skin Tumours.4th ed. Lyon, France: IARC Press; 2018 (4th ed.). Lyon, France: IARC Press.

Freedman, D. M., Looker, A. C., Abnet, C. C., Linet, M. S., & Graubard, B. I. (2010). Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res, 70(21), 8587-8597. doi:10.1158/0008-5472.can-10-1420

Gilson, D., Whittaker, S. J., Child, F. J., Scarisbrick, J. J., Illidge, T. M., Parry, E. J., . . . Morris, S. L. (2019). British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol, 180(3), 496-526. doi:10.1111/bjd.17240

Gniadecki, R., Assaf, C., Bagot, M., Dummer, R., Duvic, M., Knobler, R., . . . Whittaker, S. (2007). The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol, 157(3), 433-440. doi:10.1111/j.1365-2133.2007.07975.x

Hamilton, S. N., Wai, E. S., Tan, K., Alexander, C., Gascoyne, R. D., & Connors, J. M. (2013). Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. Int J Radiat Oncol Biol Phys, 87(4), 719-725. doi:10.1016/j.ijrobp.2013.07.019

Hathuc, V. M., Hristov, A. C., & Smith, L. B. (2017). Primary Cutaneous Acral CD8(+) T-Cell Lymphoma. Arch Pathol Lab Med, 141(11), 1469-1475. doi:10.5858/arpa.2017-0230-RA

Hoppe, R. T., Harrison, C., Tavallaee, M., Bashey, S., Sundram, U., Li, S., . . . Kim, Y. H. (2015). Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol, 72(2), 286-292. doi:10.1016/j.jaad.2014.10.014

Huen, A. O., & Kim, E. J. (2015). The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin, 33(4), 715-729. doi:10.1016/j.det.2015.05.007

Hughes, C. F., Khot, A., McCormack, C., Lade, S., Westerman, D. A., Twigger, R., . . . Prince, H. M. (2015). Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood, 125(1), 71-81. doi:10.1182/blood-2014-07-588236

Humme, D., Nast, A., Erdmann, R., Vandersee, S., & Beyer, M. (2014). Systematic review of combination therapies for mycosis fungoides. Cancer Treat Rev, 40(8), 927-933. doi:10.1016/j.ctrv.2014.06.005

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., . . . Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307. 

Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R., & Pierce, L. J. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 109(4), 650-657. doi:10.1002/cncr.22452

Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014). Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol, 70(2), 205.e201-216; quiz 221-202. doi:10.1016/j.jaad.2013.07.049

Jumbou, O., N'Guyen, J. M., Tessier, M. H., Legoux, B., & Dreno, B. (1999). Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol, 140(3), 427-431. 

Kamstrup, M. R., Gniadecki, R., Iversen, L., Skov, L., Petersen, P. M., Loft, A., & Specht, L. (2015). Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys, 92(1), 138-143. doi:10.1016/j.ijrobp.2015.01.047

Kapser, C., Herzinger, T., Ruzicka, T., Flaig, M., & Molin, S. (2015). Treatment of cutaneous T-cell lymphoma with oral alitretinoin. J Eur Acad Dermatol Venereol, 29(4), 783-788. doi:10.1111/jdv.12684

Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol, 26(3), 392-398. doi:10.1200/JCO.2007.13.3033

Kempf, W., Kazakov, D. V., & Mitteldorf, C. (2014). Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions. Am J Dermatopathol, 36(3), 197-208; quiz 209-110. doi:10.1097/DAD.0b013e318289b20e

Kempf, W., Pfaltz, K., Vermeer, M. H., Cozzio, A., Ortiz-Romero, P. L., Bagot, M., . . . Willemze, R. (2011). EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood, 118(15), 4024-4035. doi:10.1182/blood-2011-05-351346

Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., . . . Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol, 33(32), 3750-3758. doi:10.1200/JCO.2014.60.3969

Kim, Y. H., Willemze, R., Pimpinelli, N., Whittaker, S., Olsen, E. A., Ranki, A., . . . the, E. (2007). TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 110(2), 479-484. doi:10.1182/blood-2006-10-054601

Klemke, C. D. (2014). Cutaneous lymphomas. J Dtsch Dermatol Ges, 12(1), 7-28; quiz 29-30. doi:10.1111/ddg.12237

Korgavkar, K., Xiong, M., & Weinstock, M. (2013). Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol, 149(11), 1295-1299. doi:10.1001/jamadermatol.2013.5526

Krejsgaard, T., Lindahl, L. M., Mongan, N. P., Wasik, M. A., Litvinov, I. V., Iversen, L., . . . Odum, N. (2017). Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol, 39(3), 269-282. doi:10.1007/s00281-016-0594-9

Leverkus, M., Rose, C., Brocker, E. B., & Goebeler, M. (2005). Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. Br J Dermatol, 152(1), 193-194. doi:10.1111/j.1365-2133.2005.06360.x

Lin, C. T., Shiau, A. C., Tien, H. J., Yeh, H. P., Shueng, P. W., & Hsieh, C. H. (2013). An attempted substitute study of total skin electron therapy technique by using helical photon tomotherapy with helical irradiation of the total skin treatment: a phantom result. Biomed Res Int, 2013, 108794. doi:10.1155/2013/108794

Litvinov, I. V., Shtreis, A., Kobayashi, K., Glassman, S., Tsang, M., Woetmann, A., . . . Duvic, M. (2016). Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. Oncoimmunology, 5(7), e1175799. doi:10.1080/2162402x.2016.1175799

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. doi:10.1016/j.radonc.2004.09.002

Malekzadeh, F., et al. (2005). Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter. , 102.

Melchers, R. C., Willemze, R., Daniels, L. A., Neelis, K. J., Bekkenk, M. W., de Haas, E. R. M., . . . Quint, K. D. (2017). Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group. Int J Radiat Oncol Biol Phys, 99(5), 1279-1285. doi:10.1016/j.ijrobp.2017.08.010

Mirvish, J. J., Pomerantz, R. G., Falo, L. D., Jr., & Geskin, L. J. (2013). Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol, 31(4), 423-431. doi:10.1016/j.clindermatol.2013.01.009

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. doi:10.1007/s11605-010-1350-4

Nath, S. K., Yu, J. B., & Wilson, L. D. (2014). Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008. Clin Lymphoma Myeloma Leuk, 14(5), 419-423. doi:10.1016/j.clml.2013.12.018

Nicolay, J. P., & Wobser, M. (2016). Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy. J Dtsch Dermatol Ges, 14(12), 1207-1224. doi:10.1111/ddg.13164

Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., . . . Iscl/Eortc. (2007). Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 110(6), 1713-1722. doi:10.1182/blood-2007-03-055749

Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., . . . Treatment of, C. (2011). Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol, 29(18), 2598-2607. doi:10.1200/JCO.2010.32.0630

Park, J., Kwon, O., Park, K., & Chung, H. (2017). Alitretinoin treatment in mycosis fungoides with CD30-positive large cell transformation. Clin Exp Dermatol, 42(3), 341-342. doi:10.1111/ced.13046

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen, 102.

Poligone, B., & Heald, P. (2012). Menus for managing patients with cutaneous T-cell lymphoma. Semin Cutan Med Surg, 31(1), 25-32. doi:10.1016/j.sder.2011.12.002

Ponte, P., Serrao, V., & Apetato, M. (2010). Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol, 24(6), 716-721. doi:10.1111/j.1468-3083.2009.03500.x

Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., . . . group, A. s. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390(10094), 555-566. doi:10.1016/S0140-6736(17)31266-7

Prince, H. M., McCormack, C., Ryan, G., O'Keefe, R., Seymour, J. F., & Baker, C. (2003). Management of the primary cutaneous lymphomas. Australas J Dermatol, 44(4), 227-240; quiz 241-222. 

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525. 

Rubio Gonzalez, B., Zain, J., Rosen, S. T., & Querfeld, C. (2016). Tumor microenvironment in mycosis fungoides and Sezary syndrome. Curr Opin Oncol, 28(1), 88-96. doi:10.1097/cco.0000000000000243

Sauder, M. B., O'Malley, J. T., & LeBoeuf, N. R. (2017). CD30(+) Lymphoproliferative Disorders of the Skin. Hematol Oncol Clin North Am, 31(2), 317-334. doi:10.1016/j.hoc.2016.11.006

Scarisbrick, J. J., Hodak, E., Bagot, M., Stranzenbach, R., Stadler, R., Ortiz-Romero, P. L., . . . Vermeer, M. H. (2018). Blood classification and blood response criteria in mycosis fungoides and Sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer, 93, 47-56. doi:10.1016/j.ejca.2018.01.076

Seckin, D., Barete, S., Euvrard, S., Frances, C., Kanitakis, J., Geusau, A., . . . Hofbauer, G. F. (2013). Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant, 13(8), 2146-2153. doi:10.1111/ajt.12281

Senff, N. J., Noordijk, E. M., Kim, Y. H., Bagot, M., Berti, E., Cerroni, L., . . . International Society for Cutaneous, L. (2008). European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood, 112(5), 1600-1609. doi:10.1182/blood-2008-04-152850

Serrano, L., Martinez-Escala, M. E., Zhou, X. A., & Guitart, J. (2018). Pruritus in Cutaneous T-Cell Lymphoma and Its Management. Dermatol Clin, 36(3), 245-258. doi:10.1016/j.det.2018.02.011

Sharp, L., Johansson, H., Hatschek, T., & Bergenmar, M. (2013). Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast, 22(5), 634-638. doi:10.1016/j.breast.2013.07.047

Sokolowska-Wojdylo, M., Lugowska-Umer, H., & Maciejewska-Radomska, A. (2013). Oral retinoids and rexinoids in cutaneous T-cell lymphomas. Postepy Dermatol Alergol, 30(1), 19-29. doi:10.5114/pdia.2013.33375

Spaccarelli, N., & Rook, A. H. (2015). The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin, 33(4), 731-745. doi:10.1016/j.det.2015.05.008

Stadler, R., Otte, H. G., Luger, T., Henz, B. M., Kuhl, P., Zwingers, T., & Sterry, W. (1998). Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood, 92(10), 3578-3581. 

Suga, H., Sugaya, M., Miyagaki, T., Ohmatsu, H., Kawaguchi, M., Takahashi, N., . . . Sato, S. (2014). Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma. Clin Cancer Res, 20(16), 4339-4348. doi:10.1158/1078-0432.ccr-14-0077

Swerdlow, S. H. (2017). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer.

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., . . . Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375-2390. doi:10.1182/blood-2016-01-643569

Talpur, R., Bassett, R., & Duvic, M. (2008). Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol, 159(1), 105-112. doi:10.1111/j.1365-2133.2008.08612.x

Thomas, T. O., Agrawal, P., Guitart, J., Rosen, S. T., Rademaker, A. W., Querfeld, C., . . . Mittal, B. B. (2013). Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys, 85(3), 747-753. doi:10.1016/j.ijrobp.2012.05.034

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. doi:10.1093/bja/aen401

Trautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., . . . Knobler, R. (2017). European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017. Eur J Cancer, 77, 57-74. doi:10.1016/j.ejca.2017.02.027

Vakeva, L., Ranki, A., & Hahtola, S. (2012). Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol, 92(3), 258-263. doi:10.2340/00015555-1359

Weber, F., Schmuth, M., Sepp, N., & Fritsch, P. (2005). Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. Acta Derm Venereol, 85(4), 329-332. doi:10.1080/00015550510032814

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., . . . Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. doi:10.1016/j.radonc.2004.07.032

Whittaker, S., Ortiz, P., Dummer, R., Ranki, A., Hasan, B., Meulemans, B., . . . Karrasch, M. (2012). Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol, 167(3), 678-687. doi:10.1111/j.1365-2133.2012.11156.x

Wieser, I., Oh, C. W., Talpur, R., & Duvic, M. (2016). Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol, 74(1), 59-67. doi:10.1016/j.jaad.2015.09.013

Wilcox, R. A. (2016). Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol, 91(10), 1052-1055. doi:10.1002/ajh.24462

Wilcox, R. A. (2018). Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Am J Hematol, 93(11), 1427-1430. doi:10.1002/ajh.25224

Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019). The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 133(16), 1703-1714. doi:10.1182/blood-2018-11-881268

Willemze, R., Hodak, E., Zinzani, P. L., Specht, L., Ladetto, M., & Committee, E. G. (2018). Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 29(Supplement_4), iv30-iv40. doi:10.1093/annonc/mdy133

Willemze, R., Jaffe, E. S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S. H., . . . Meijer, C. J. (2005). WHO-EORTC classification for cutaneous lymphomas. Blood, 105(10), 3768-3785. doi:10.1182/blood-2004-09-3502

Willerslev-Olsen, A., Krejsgaard, T., Lindahl, L. M., Litvinov, I. V., Fredholm, S., Petersen, D. L., . . . Odum, N. (2016). Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood, 127(10), 1287-1296. doi:10.1182/blood-2015-08-662353

Wong, H. K., Mishra, A., Hake, T., & Porcu, P. (2011). Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol, 155(2), 150-166. doi:10.1111/j.1365-2141.2011.08852.x

Xue, J., Liu, C., & Liu, Y. (2017). Photodynamic therapy as an alternative treatment for relapsed or refractory mycosis fungoides: A systemic review. Photodiagnosis Photodyn Ther, 17, 87-91. doi:10.1016/j.pdpdt.2016.11.010

Yahalom, J., Illidge, T., Specht, L., Hoppe, R. T., Li, Y.-X., Tsang, R., & Wirth, A. (2015). Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics, 92(1), 11-31. doi:https://doi.org/10.1016/j.ijrobp.2015.01.009

Zackheim, H. S. (2003). Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther, 16(4), 283-287. 

Zinzani, P. L., Baliva, G., Magagnoli, M., Bendandi, M., Modugno, G., Gherlinzoni, F., . . . Tura, S. (2000). Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol, 18(13), 2603-2606. doi:10.1200/JCO.2000.18.13.2603

 

Nästa kapitel
24 Vårdprogramgruppen